Glyburide Disposition During Pregnancy

摘要: During pregnancy, 5-14% of women are diagnosed with gestational diabetes mellitus (GDM) and the incidence has been increasing (Jovanovic & Pettitt, 2001; Paglia Coustan, 2011). While insulin treatment is still “gold standard” therapy for controlling maternal glycemia, use oral anti-diabetic agents such as glyburide metformin begun to change standard care (Maymone et al., Anti-diabetic drugs often titrated over a prolonged period time achieve glycemic control. Prolonged hyperglycemia increases likelihood adverse fetal/neonatal outcomes. Thus, quickly achieving control during pregnancy can significantly reduce occurrence certain perinatal outcomes (Karakash Einstein, Glyburide second generation sulfonylurea (Feldman, 1985). lowers blood sugar levels by stimulating pancreas secrete helping body efficiently. Considerable data in literature suggest that may be safe alternative GDM due its similar efficacy low fetal distribution (Nicholson Baptiste-Roberts, 2011; Maymone Physiological biochemical changes occur alter pharmacokinetics glyburide, thus affecting safety drug both mother fetus. Understanding pregnancy-induced disposition (including exposure) will important optimizing dosage guidelines pregnancy. In this chapter, current knowledge on GDM, pregnancy-related effects well placental transport metabolism summarized.